Monthly
US$200
Billed every month
Sign in to subscribeCrizotinib Capsules
As of 13 November 2026, for Crizotinib Capsules, 7 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 3 holders.
Companies, stages and changes, with each record available on this page.
Listed in the US FDA Orange Book as XALKORI (NDA 202570, PF PRISM CV).
No changes recorded by this site in the last 90 days
Complete CDE snapshot: 2026/11/13 06:42
Current coverage may be incomplete
US Orange Book listing
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 1 of 1 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Capsules. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
Same dosage form
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| XALKORI | PF PRISM CV | NDA 202570 · Product no. 001, 002 | CAPSULE | ORAL | HUMAN PRESCRIPTION DRUG | 2011/08/26 |
Other dosage forms of the same ingredient
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| XALKORI | PF PRISM CV | NDA 217581 · Product no. 001, 002, 003 | CAPSULE, PELLETS | ORAL | HUMAN PRESCRIPTION DRUG | 2023/09/07 |
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders3View records ↓
Under-review filings7View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers3View records ↓
API companies with A status3View records ↓
Chemical-drug catalogue
Loaded records: 3 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 2 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | 国药准字H20263240 | 2026/01/27 | 0.25g | Generic approved under the new chemical-drug registration classification | CDE |
| Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | 国药准字H20263239 | 2026/01/27 | 0.2g | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangsu Wan Bang Sheng Hua Pharmaceuticals Group Co., Ltd. romanized | Jiangsu Wan Bang Sheng Hua Pharmaceuticals Group Co., Ltd. romanized | 国药准字H20234492 | 2023/11/21 | 200mg | Generic approved under the new chemical-drug registration classification | CDE |
| Jiangsu Wan Bang Sheng Hua Pharmaceuticals Group Co., Ltd. romanized | Jiangsu Wan Bang Sheng Hua Pharmaceuticals Group Co., Ltd. romanized | 国药准字H20234491 | 2023/11/21 | 250mg | Generic approved under the new chemical-drug registration classification | CDE |
| Pfizer Ltd. | Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg | H20171008;H20171011;H20171012 | 2013/01/22 | 200mg | Imported originator drug | CDE |
| Pfizer Ltd. | Pfizer Manufacturing Deutschland GmbH, Betriebsstatte Freiburg | H20171009;H20171013;H20171014 | 2013/01/22 | 250mg | Imported originator drug | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 3 distinct approval numbers and 2 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Chongqing Hua Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20255702 | 0.25g | Category B | XL01EDK116E001010101007 | NHSA |
| PFIZER EUROPE MA EEIG | 国药准字HJ20171011 | 200mg | Category B | XL01EDK116E001010178718 | NHSA |
| PFIZER EUROPE MA EEIG | 国药准字HJ20171011 | 200mg | Category B | XL01EDK116E001010278718 | NHSA |
| PFIZER EUROPE MA EEIG | 国药准字HJ20171013 | 250mg | Category B | XL01EDK116E001020178718 | NHSA |
| PFIZER EUROPE MA EEIG | 国药准字HJ20171013 | 250mg | Category B | XL01EDK116E001020278718 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 7 filings and 4 distinct first applicants.
Supplement 2 · Import re-registration 2 · Generic 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | CYHB2600764 | Supplement | 2026/04/16 | Not stated by source | CDE |
| Kun Shan Long Deng Rui Di Pharmaceutical Co., Ltd. romanized | CYHB2600763 | Supplement | 2026/04/16 | Not stated by source | CDE |
| PFIZER EUROPE MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | JYHZ2600156 | Import re-registration | 2026/06/30 | Not stated by source | CDE |
| PFIZER EUROPE MA EEIG; Pfizer Manufacturing Deutschland GmbH; Pfizer Investment Co. Ltd. | JYHZ2600155 | Import re-registration | 2026/06/30 | Not stated by source | CDE |
| Chongqing Sheng Hua Xi Pharma Co., Ltd. romanized | CYHS2600730 | Generic | 2026/03/27 | Not stated by source | CDE |
| Beijing Kang Li Sheng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangxi Shan Xiang Pharma Co., Ltd. romanized | CYHS2600661 | Generic | 2026/03/13 | Not stated by source | CDE |
| Beijing Kang Li Sheng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangxi Shan Xiang Pharma Co., Ltd. romanized | CYHS2600660 | Generic | 2026/03/13 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Chongqing Sheng Hua Xi Pharma Co., Ltd. romanized | CYHS2600730 | Generic | 2026/03/27 | Not stated by source | CDE |
| Beijing Kang Li Sheng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangxi Shan Xiang Pharma Co., Ltd. romanized | CYHS2600661 | Generic | 2026/03/13 | Not stated by source | CDE |
| Beijing Kang Li Sheng Pharmaceuticals Technology Kai Fa Co., Ltd. romanized; Jiangxi Shan Xiang Pharma Co., Ltd. romanized | CYHS2600660 | Generic | 2026/03/13 | Not stated by source | CDE |
API registrations
Non-component matches: 3 companies with A status and 4 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 克唑替尼 · No verified English name | Chongqing Sheng Hua Xi Pharma Co., Ltd. romanized | Y20250001018 | I | Exact ingredient | 2025/11/11 | CDE |
| 克唑替尼 · No verified English name | Han Rui Pharma (Jing Men) Co., Ltd. romanized | Y20250000557 | I | Exact ingredient | 2025/06/10 | CDE |
| 克唑替尼 · No verified English name | Hetero Labs Limited | Y20250000129 | I | Exact ingredient | 2025/03/14 | CDE |
| 克唑替尼 · No verified English name | Chongqing Sheng Kai Pharmaceutical Co., Ltd. romanized | Y20230001144 | A | Exact ingredient | 2025/06/24 | CDE |
| 克唑替尼 · No verified English name | MSN LABORATORIES PRIVATE LIMITED | Y20230001230 | A | Exact ingredient | 2026/01/16 | CDE |
| 克唑替尼 · No verified English name | Xu Zhou Wan Bang Jin Qiao Pharmaceutical Co., Ltd. romanized | Y20210000680 | A | Exact ingredient | 2023/11/29 | CDE |
| 克唑替尼 · No verified English name | Xu Zhou Wan Bang Jin Qiao Pharmaceutical Co., Ltd. romanized | Y20200001276 | I | Exact ingredient | 2021/01/05 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Crizotinib Capsules
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy